Chemoimmunotherapy
Chemoimmunotherapy is a cancer-treatment strategy that combines cytotoxic chemotherapy with immunotherapy, most commonly an immune checkpoint inhibitor or another immune-modulating treatment.
Chemoimmunotherapy is a cancer-treatment strategy that combines cytotoxic chemotherapy with immunotherapy, most commonly an immune checkpoint inhibitor or another immune-modulating treatment. Chemotherapy can reduce tumor burden and may promote immunogenic cell death, antigen release, and changes in the tumor microenvironment, while immunotherapy is intended to enhance or restore antitumor immune activity. The combined approach is therefore used to address both tumor-cell proliferation and immune escape.
The specific regimen depends on the cancer type, disease stage, biomarkers, and treatment setting. In current research, chemoimmunotherapy is being evaluated in advanced non-small cell lung cancer, small-cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, thoracic tumors, and other malignancies. Commonly studied components include cisplatin, paclitaxel, pembrolizumab, and other checkpoint inhibitors. Outcomes of interest include objective response rate, progression-free survival, overall survival, hazard ratios, lymphopenia, and changes in the tumor microenvironment. Related strategies include combining chemoimmunotherapy with thoracic radiotherapy or using local delivery systems designed to enhance immunogenic cell death.
Where the papers sit
10 papers from the last 6 months study chemoimmunotherapy directly · updated from PubMed 2 Nov 2026
Study type 1 clinical trial · 4 observational · 2 human data · 3 preclinical
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Lung Cancer Treatment Optimization
Lung cancer treatment is moving toward greater personalization of chemoimmunotherapy. ctDNA tumor fraction is being evaluated for selecting regimens in advanced non-small cell lung cancer, while thoracic radiotherapy is tested in elderly patients and circadian treatment timing in extensive-stage small cell lung cancer. Progression-free survival and overall survival remain the main endpoints. Validation is still needed before biomarker, radiation, or timing strategies become routine.
4 papers · 40%
-
Clinical Cancer Treatment Outcomes
Combination treatment is being assessed through survival, progression-free survival, and adverse-event endpoints across advanced cancers. Esophageal squamous cell carcinoma studies compare chemoimmunotherapy with or without radiotherapy, while neoadjuvant afatinib is being explored in locally advanced head and neck squamous cell carcinoma. Long-term neuroblastoma follow-up adds a distinct survivorship perspective. The differing diseases and regimens support outcome-focused comparison more than a single therapeutic direction.
3 papers · 30%
-
Tumor-Targeted Combination Delivery
Combination therapy is moving toward delivery systems that concentrate chemotherapy and immune activation within tumors. Engineered probiotics, copper-complex plasmid carriers targeting PD-L1, and hyaluronic acid hydrogels co-loaded with cisplatin and MSA-2 seek to improve immunogenicity and reshape the tumor microenvironment. The approaches remain preclinical and emphasize local, multifunctional treatment. Translation will depend on delivery control, safety, and durable antitumor responses.
3 papers · 30%
The efficacy of chemoimmunotherapy depends on when it is administered, not only on which agents it contains
The ES-SCLC timing cohort and the NSCLC LungTIME-C01 commentary both identify earlier administration as associated with substantially better progression-free and overall outcomes than later administration, challenging the assumption that chemoimmunotherapy is a time-invariant regimen whose efficacy is determined solely by its drugs. Treatment scheduling therefore becomes a potentially modifiable component of efficacy, although the NSCLC analysis notes that chemotherapy chronopharmacology, circadian immune regulation, and healthcare-delivery factors may also contribute 42788839Sep 42258320Jun.
Tumor-homing bacteria can function as an integrated in situ chemoimmunotherapy factory
The MC38 and B16-F10 murine tumor study used engineered Escherichia coli Nissle 1917 not merely as a carrier but as a living platform that converted 5-fluorocytosine into 5-fluorouracil while simultaneously producing an IL-15 superagonist and a PD-L1-blocking nanobody inside tumors. This assigns chemoimmunotherapy a new role as locally manufactured, self-targeted therapy capable of generating systemic antitumor immunity and durable immune memory, rather than as conventionally co-administered cytotoxic and immune-modulating drugs 42748218Sep.
Papers
The 10 papers from the last 6 months that study chemoimmunotherapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Lung Cancer Treatment Optimization (4)
- Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer. Oncoimmunology · 25 Sept 2026 PMID 42788839
- Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42440365
- Cancer Chemoimmunotherapy: Time Will Tell. Cancer immunology research · 8 Jun 2026 PMID 42258320
- Chemoimmunotherapy With or Without Thoracic Radiotherapy for Elderly Patients in Advanced Non-Small Cell Lung Cancer. International journal of cancer · 13 May 2026 PMID 42121314
Clinical Cancer Treatment Outcomes (3)
- Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731876
- Efficacy analysis of first-line chemoimmunotherapy with or without radiotherapy in stage IVB esophageal squamous cell carcinoma: a real-world study. Future oncology (London, England) · 27 Jul 2026 PMID 42504461
- Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatric blood & cancer · 23 Jul 2026 PMID 42487540
Tumor-Targeted Combination Delivery (3)
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
- Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy. Biomedical materials (Bristol, England) · 15 Jul 2026 PMID 42456758
- Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197
By study type
Clinical trials (1)
- Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731876
Observational studies and case reports (4)
- Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer. Oncoimmunology · 25 Sept 2026 PMID 42788839
- Efficacy analysis of first-line chemoimmunotherapy with or without radiotherapy in stage IVB esophageal squamous cell carcinoma: a real-world study. Future oncology (London, England) · 27 Jul 2026 PMID 42504461
- Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatric blood & cancer · 23 Jul 2026 PMID 42487540
- Chemoimmunotherapy With or Without Thoracic Radiotherapy for Elderly Patients in Advanced Non-Small Cell Lung Cancer. International journal of cancer · 13 May 2026 PMID 42121314
Human data, design not indexed (2)
- Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42440365
- Cancer Chemoimmunotherapy: Time Will Tell. Cancer immunology research · 8 Jun 2026 PMID 42258320
Preclinical: animal, cell and lab studies (3)
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
- Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy. Biomedical materials (Bristol, England) · 15 Jul 2026 PMID 42456758
- Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-09-16. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.